David Alan Campbell, President and CEO at Janux Therapeutics, Inc. (JANX), sold 50,000 shares at $52.04 ($2.6M) on 2024-11-25, disclosed to the SEC on 2024-11-27.
Scheduled sale ($2.6M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $51.43 | 18,281 | $940K | 36.4% |
| 2 | $51.43 | 18,281 | $940K | 36.4% |
| 3 | $52.04 | 6,719 | $350K | 13.6% |
| 4 | $52.04 | 6,719 | $350K | 13.6% |
| Total | $51.59 avg | 50,000 | $2.6M | 100% |
| Filing → |
| JANX | SELL | 2024-12-27 | $1.4M | — | Filing → |
| JANX | SELL | 2024-12-03 | $1.0M | — | Filing → |
| JANX | SELL | 2024-10-30 | $2.7M | — | Filing → |